- P-ISSN 2233-4203
- E-ISSN 2093-8950
- Log In/Sign Up
- P-ISSN2233-4203
- E-ISSN2093-8950
- ESCI, SCOPUS, KCI
Article Detail
Home > Article Detail
Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations
Mass Spectrometry Letters / Mass Spectrometry Letters, (P)2233-4203; (E)2093-8950
2015, v.6 no.2, pp.38-42
https://doi.org/10.5478/MSL.2015.6.2.38
(Institute of Technical Education and Research (ITER))
(Institute of Technical Education and Research (ITER))
(Institute of Technical Education and Research (ITER))
Paul,
S. K., &
Dash,
U.
N.
(2015). Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations. Mass Spectrometry Letters, 6(2), 38-42, https://doi.org/10.5478/MSL.2015.6.2.38
- Downloaded
- Viewed
Abstract
Roflumilast analogs are a group of drugs which act as selective photodiesterase (PDE-4) inhibitor for the treatment severe chronic pulmonary disease associated with chronic brochnonities. Structural identification of degradation products using high resolution mass spectrometry and theoretical investigation by density functional theory have been successfully carried out on roflumilast to identify four degradation products namely, 3,5-dichloropyridin-4-amine, N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxy benzamide, N-(3,5-dichloropyridin-4-yl)-3-(cyclopropylmethoxy)-4-(difluoromethoxy) benzamide and 3-(cyclopropylmethoxy)-N- (3,5-dichloro-1-oxidopyridin-4-yl)-4-(difluoro methoxy) benzamide, generated in alkali, acidic and oxidative conditions.
- keywords
- Roflumilast, Mass Spectrometry, Degradation products, DFT
Reference
1
Beghe, B.. (2013). . American Journal of Respiratory and Critical Care Medicine, 188, 271-.
2
Giembycz, Mark, A.. (2010). . Drug Design, Development and Therapy, 4, 147-.
3
Boland, S.. (2014). . Bioorg. Med. Chem. Lett, , -.
4
ICH. (2006). Impurities in New Drug Products Q3B (R2) (-). International Conference on Harmonization Guidance for Industry.
5
ICH. (2003). Stability Testing of New Drug Substances and Products Q1A (R2) (-). International Conference on Harmonization, IFPMA.
6
ICH. (2006). Impurities in New Drug Substances Q3A (R2) (-). International Conference on Harmonization, IFPMA.
7
Tarek, S. B.. (2014). :Bulletin of Faculty of Pharmacy Cairo University.
8
Barhate, V. D.. (2010). . Indian J. Pharm. Sci, 72, 401-.
9
Sun, C.. (2013). . Research on Chemical Intermediates, 1, -.
10
Zhang, H.. (2014). . Journal of Chemical Research, 38, 507-.
11
Lin, Y.. (2013). . Research on Chemical Intermediates, 39, 3111-.
12
Alex, A.. (2009). . Rapid Commun. Mass Spectrom, 23, 2619-.
13
Wright, P.. (2010). . Rapid Commun. Mass Spectrom, 24, 1025-.
14
Wright, P.. (2014). . Rapid Commun. Mass Spectrom, 28, 1127-.
- Submission Date
- 2015-03-18
- Revised Date
- 2015-04-12
- Accepted Date
- 2015-04-20
Other articles from this issue
- Sample Preparation for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry
- Enrichment Strategies for Identification and Characterization of Phosphoproteome
- Identification of Degradation Products in the Phosphodiesterase (PDE-4) Inhibitor Roflumilast Using High Resolution Mass Spectrometry and Density Functional Theory Calculations
- Soft Ionization of Metallo-Mefenamic Using Electrospray Ionization Mass Spectrometry
- Evaluation of Metabolic Stability of Kinsenoside, an Antidiabetic Candidate, in Rat and Human Liver Microsomes
- Investigation on Lipopolysaccharide Activated Microglia by Phosphoproteomics and Phosphoinositide Lipidomics
- more
Recommanded Articles
This website recommended the use the Chrome browser for journal website.